Abstract:Receptor Interacting Protein Kinase 1 (RIPK1) and caspase-8 (Casp8) jointly orchestrate apoptosis, a key mechanism for eliminating developing T cells which have autoreactive or improperly arranged T cell receptors. Mutations in the scaffolding domain of Ripk1 gene have been identified in humans with autoinflammatory diseases like Cleavage Resistant RIPK1 Induced Autoinflammatory (CRIA) and Inflammatory Bowel Disease. RIPK1 protein also contributes to conventional T cell differentiation and peripheral T cell homeostasis through its scaffolding domain in a cell death independent context. Ripk1 deficient mice do not survive beyond birth, so we have studied the function of this kinase in vivo against a backdrop Ripk3 and Casp8 deficiency which allows the mice to survive to adulthood. These studies reveal a key role for RIPK1 in mediating NK1.1 expression, including on thymic iNKT cells, which is a key requirement for thymic stage 2 to stage 3 transition as well as iNKT cell precursor development. These results are consistent with RIPK1 mediating responses to TcR engagement, which influence NK1.1 expression and iNKT cell thymic development. We also used in vivo and in vitro stimulation assays to confirm a role for both Casp8 and RIPK1 in mediating iNKT cytokine effector responses. Finally, we also noted expanded and hyperactivated iNKT follicular helper (iNKTFH) cells in both DKO (Casp8-, Ripk3- deficient) and TKO mice (Ripk1-, Casp8-, Ripk3- deficient). Thus, while RIPK1 and Casp8 jointly facilitate iNKT effector function, RIPK1 uniquely influenced thymic iNKT cell development most likely by regulating molecular responses to T cell receptor engagement. iNKT developmental and functional aberrances were not evident in mice expressing a kinase-dead version of RIPK1 (RIPK1kd), indicating that the scaffolding function of this protein exerts the critical regulation of iNKT cells. Our findings suggest that small molecule inhibitors of RIPK1 could be used to regulate iNKT cell development and effector function to alleviate autoinflammatory conditions in humans.

Correction to: RIPK1 prevents TRADD-driven, but TNFR1 independent, apoptosis during development

Correction: NF-κB regulated expression of A20 controls IKK dependent repression of RIPK1 induced cell death in activated T cells

Erratum: Advances in RIPK1 kinase inhibitors

RIPK1 protects naive and regulatory T cells from TNFR1-induced apoptosis

Correction: Corrigendum: The transcriptional coactivator TAZ regulates reciprocal differentiation of T H 17 cells and T reg cells

The interaction between RIPK1 and FADD controls perinatal lethality and inflammation

The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation

Correction To: RIP1 Protects Melanoma Cells from Apoptosis Induced by BRAF/MEK Inhibitors.

Author Correction: Inhibition of RIPK1-dependent regulated acinar cell necrosis provides protection against acute pancreatitis via the RIPK1/NF-κB/AQP8 pathway

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

A unique death pathway keeps RIPK1 D325A mutant mice in check at embryonic day 10.5

RIPK1 deficiency prevents thymic NK1.1 expression and subsequent iNKT cell development

RIPK1-Associated Inborn Errors of Innate Immunity

RIP1 Kinase Activity-Dependent Roles in Embryonic Development of Fadd-deficient Mice

Tyrosine Phosphorylation Regulates RIPK1 Activity to Limit Cell Death and Inflammation.

A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1

Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis

Correction: EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401

Retraction Note: The NAD-dependent deacetylase SIRT2 is required for programmed necrosis

Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo.

RIP1-dependent linear and nonlinear recruitments of caspase-8 and RIP3 respectively to necrosome specify distinct cell death outcomes